Merck’s investigational inactivated varicella zoster virus vaccine reduced incidence
Merck announced the first Phase 3 study results for V212, the company’s investigational inactivated varicella zoster virus vaccine (VZV) for the prevention of herpes zoster. In the trial, V212 met its primary endpoint and reduced the incidence of confirmed HZ cases by an estimated 64 percent. February 24, 2017